In vivo assessment of aging changes in serotonin function.
Meltzer
C C
CC
Reynolds
C F
CF
D000368:Aged; D000544:Alzheimer Disease / Q000503:physiopathology*; D001921:Brain / Q000000981:diagnostic imaging / Q000502:physiology / Q000503:physiopathology*; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics; D003866:Depressive Disorder / Q000503:physiopathology*; D006801:Humans; D008297:Male; D010879:Piperazines / Q000493:pharmacokinetics; D011725:Pyridines / Q000493:pharmacokinetics; D011985:Receptors, Serotonin / Q000032:analysis / Q000378:metabolism; D044263:Receptors, Serotonin, 5-HT1; D012701:Serotonin / Q000502:physiology*; D012702:Serotonin Antagonists / Q000493:pharmacokinetics; D014055:Tomography, Emission-Computed
D002250:Carbon Radioisotopes; D010879:Piperazines; D011725:Pyridines; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D012702:Serotonin Antagonists; D012701:Serotonin; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide